Bank lending expands by 13.9%, year-on-year, in October 2022
Preliminary data show that outstanding loans of universal and commercial banks (U/KBs), net of reverse repurchase (RRP) placements with the Bangko Sentral ng Pilipinas (BSP), grew by 13.9 percent year-on-year in October from a 13.4-percent rise in September. On a month-on-month seasonally-adjusted basis, outstanding universal and commercial bank loans, net of RRPs, went up by 1.1 percent.
Outstanding loans to residents, net of RRPs, also increased by 13.4 percent in October after growing by 13.1 percent in the previous month.
Outstanding loans for production activities rose by 12.5 percent in October, from 12.3-percent expansion in September, driven largely by the growth in loans to key industries such as real estate activities (14.0 percent); manufacturing (17.7 percent); wholesale and retail trade, repair of motor vehicles and motorcycles (11.5 percent); financial and insurance activities (12.8 percent); information and communication (25.0 percent); and electricity, gas, steam, and airconditioning supply (10.9 percent).
Similarly, consumer loans to residents increased by 22.6 percent in October from 20.6 percent (revised) in the previous month, due mainly to the year-on-year increase in credit card loans, motor vehicle loans, and salary-based general purpose consumption loans.
Outstanding loans to non-residents[1] grew by 33.0 percent in October from 26.6-percent expansion in September.
The sustained growth in credit activity and ample liquidity will continue to support the recovery of economic activity and domestic demand.
Looking ahead, the BSP will continue to take all necessary action to ensure that liquidity and bank lending conditions remain consistent with promoting price and financial stability.
[1] Outstanding loans to non-residents include loans by UKB’s foreign currency deposit units (FCDUs) to non-residents
Comments (0)
LEAVE A REPLY
No comments yet
Be the first to share your thoughts!
Related Articles

BIR expands VAT-exempt medicines list
The Bureau of Internal Revenue has expanded the list of value-added tax-exempt medicines to 2,277 products following the issuance of Revenue Memorandum Circular No. 87-2026, a move aimed at lowering healthcare costs for Filipinos managing chronic and life-threatening illnesses. The updated list, endorsed by the Food and Drug Administration under Republic Act No. 10963, or


